Related Experiment Video
Updated: Mar 24, 2026
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
Low-dose vs standard-dose nintedanib at initiation in fibrosing interstitial lung disease: a target-trial emulation
Shota Kaburaki, Toru Tanaka1, Koichiro Kamio1
1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Background:
Early intolerance to nintedanib may shorten time spent on treatment. Whether initiating treatment at 100 mg vs 150 mg twice daily improves treatment persistence for 12 months without compromising lung function is uncertain.
Objectives:
To estimate the effects of 100 mg vs 150 mg at initiation on 12-month time on treatment and ∼1-year lung function.
Methods:
An observational emulation of an individually randomized target trial in a single-center new-user cohort was conducted. Baseline confounding was addressed using stabilized inverse probability of treatment weighting (IPTW) with 1st to 99th percentile trimming. The primary estimand was the difference in the restricted mean time on treatment (RMST) over 12 months. Key secondary estimands were the IPTW-adjusted absolute risk difference (RD) in 12-month treatment discontinuation (accounting for competing death) and the mean difference in change in forced vital capacity (ΔFVC) %predicted at ∼12 months among survivors. Uncertainty was quantified by patient-level bootstrapping.
Results:
Among 172 initiators (100 mg, n = 94; 150 mg, n = 78), 100-mg initiation extended the 12-month RMST by 52.9 days (95% CI, 11.8-97.1 days) and decreased the 12-month discontinuation risk (cumulative incidence function, 0.135 vs 0.281; RD, 0.146). The ΔFVC %predicted was broadly similar among survivors, but the estimates were imprecise.
Conclusions:
In this target-trial emulation, starting at 100 mg twice daily improved 12-month treatment persistence. One-year FVC %predicted estimates among survivors were broadly similar but imprecise and should be interpreted with caution; a start-low, escalate-as-tolerated policy warrants prospective evaluation.
Related Concept Videos
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions